Orthofix Medical, Inc.

As of September 19, 2025, Orthofix Medical, Inc. is in a mildly bearish trend, with daily moving averages and monthly indicators signaling weakness, while the stock has underperformed the S&P 500 with a year-to-date return of -14.89% compared to the index's 13.31%.

As of September 19, 2025, Orthofix Medical, Inc. has shifted to a mildly bearish trend, with daily moving averages and monthly indicators signaling bearish sentiment, despite some weekly bullish signals, and the stock has underperformed the S&P 500 with a return of -9.75%.

As of July 21, 2025, Orthofix Medical, Inc. shows a mildly bearish trend with mixed technical indicators, including bullish weekly MACD and Bollinger Bands, but mildly bearish daily moving averages and KST, suggesting caution in the overall outlook.

As of April 30, 2021, Orthofix Medical, Inc. is considered a risky investment due to its negative performance metrics and disappointing stock returns, indicating it is overvalued compared to its peers and the S&P 500.

As of April 30, 2021, Orthofix Medical, Inc. is considered overvalued and risky, with significant financial distress indicated by negative key ratios and a year-to-date return of -38.14%, underperforming the S&P 500.

As of May 6, 2025, Orthofix Medical, Inc. exhibits a bearish trend, supported by bearish MACD signals, moving averages, and Bollinger Bands, indicating significant weakness compared to the S&P 500.

As of March 2022, the management team of Orthofix Medical, Inc. includes Independent Chairman Ronald Matricaria, CEO Jon Serbousek, and Independent Directors Jason Hannon, James Hinrichs, Alexis Lukianov, Lilly Marks, and Michael Paolucci. They oversee the company's operations and strategic direction.

Orthofix Medical, Inc. is a global medical device company specializing in reconstructive and regenerative orthopedic and spine solutions. As of March 2025, it reported net sales of $194 million and a market cap of $412.18 million.

As of Jun 18, Orthofix Medical, Inc. has a market capitalization of 412.18 million and reported net sales of 804.54 million with a net profit of -143.07 million over the latest four quarters.